EXPERT Q&A
EXPERT Q&A
07/17/2024
In this Q&A, Brittany A. Davidson, MD, discusses navigating goals-of-care conversations in gynecologic oncology, including how to identify patients at high risk of death who might benefit from a timely...
07/17/2024
EXPERT Q&A
EXPERT Q&A
07/17/2024
In this Q&A, Brittany A. Davidson, MD, discusses navigating goals-of-care conversations in gynecologic oncology, including how to identify patients at high risk of death who might benefit from a timely...
07/17/2024
EXPERT Q&A
EXPERT Q&A
07/17/2024
In this Q&A, Brittany A. Davidson, MD, discusses navigating goals-of-care conversations in gynecologic oncology, including how to identify patients at high risk of death who might benefit from a timely...
07/17/2024
EXPERT Q&A
EXPERT Q&A
07/17/2024
In this Q&A, Brittany A. Davidson, MD, discusses navigating goals-of-care conversations in gynecologic oncology, including how to identify patients at high risk of death who might benefit from a timely...
07/17/2024
Expert Q&A
Expert Q&A
06/23/2024

Elmar A. Joura, MD

Elmar A. Joura, MD
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
06/23/2024
Expert Q&A
Expert Q&A
06/23/2024

Elmar A. Joura, MD

Elmar A. Joura, MD
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
06/23/2024
Expert Q&A
Expert Q&A
06/23/2024

Elmar A. Joura, MD

Elmar A. Joura, MD
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
06/23/2024
Expert Q&A
Expert Q&A
06/23/2024

Elmar A. Joura, MD

Elmar A. Joura, MD
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
06/23/2024
Expert Q&A
Expert Q&A
06/23/2024

Elmar A. Joura, MD

Elmar A. Joura, MD
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
06/23/2024
Expert Q&A
Expert Q&A
06/23/2024

Elmar A. Joura, MD

Elmar A. Joura, MD
In this interview, Elmar Joura, MD, answers questions about the long-term follow-up data on sustained immunogenicity and safety for the 9-valent human papillomavirus (HPV) vaccine, including indications,...
06/23/2024